ITOG Registries
Our registries were established to address critical knowledge gaps in rare and complex thyroid cancers. By systematically collecting high-quality clinical, molecular, treatment, and outcomes data across leading institutions worldwide, ITOG transforms real-world experience into actionable scientific insight.
Because many thyroid cancer subtypes are uncommon, progress depends on collaboration. ITOG’s registry platform enables participating centers to aggregate data at scale, identify emerging patterns, generate hypotheses, and inform future prospective trials.
Medullary Thyroid Cancer Registry
Medullary thyroid cancer (MTC) is a rare form of thyroid cancer that often requires highly specialized care. Because it is uncommon, doctors and researchers have fewer opportunities to study large numbers of patients, making it harder to answer important questions about treatment and long-term outcomes.
The ITOG Medullary Thyroid Cancer Registry was created to bring experts together and learn from shared experiences.
This registry gathers information from participating centers about how patients are diagnosed, treated, and followed over time. By combining data from multiple institutions, ITOG can better understand:
By learning from real-world experience, the Medullary Registry helps improve care today while guiding the development of better treatments for the future.
Neoadjuvant Registry
In some advanced thyroid cancers, doctors may use medication before surgery to shrink tumors and make surgery safer or more effective. This approach is still evolving, and many questions remain about who benefits most and what the long-term results look like.
The ITOG Neoadjuvant Registry was established to better understand this treatment approach.
The registry collects information about patients who receive therapy before surgery, including how their tumors respond, how surgery is affected, and how patients do afterward.
By sharing experiences across institutions, ITOG aims to:
This registry ensures that new treatment strategies are carefully studied and guided by evidence, helping physicians make informed decisions for their patients.
Redifferentiation Registry
Some thyroid cancers stop responding to standard radioactive iodine treatment, which can limit options for patients. New therapies are being explored that may help restore the cancer’s ability to respond to radioactive iodine, offering renewed treatment possibilities.
The ITOG Redifferentiation Registry was developed to study this promising approach. This registry gathers information on patients who receive therapies designed to “re-sensitize” their cancer to radioactive iodine. By tracking how patients respond and how they do over time, ITOG hopes to better understand:
Through collaboration and shared learning, the Redifferentiation Registry supports continued progress in expanding treatment options for patients with advanced thyroid cancer.
Get Involved with ITOG Registries
ITOG registries are built on collaboration. We welcome engagement from investigators, institutions, and industry partners committed to advancing thyroid cancer research.
